This inventor holds 1 USPTO granted patent. Top assignee: Abclon Inc.. Active years: 2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2024
Title: Innovations by Carl Erik Mathias Uhlen
Introduction
Carl Erik Mathias Uhlen is a notable inventor based in Stockholm, Sweden. He has made significant contributions to the field of biotechnology, particularly in the development of innovative therapeutic solutions for cancer treatment.
Latest Patents
Uhlen holds a patent for a "Switch molecule and switchable chimeric antigen receptor." This invention relates to a switch molecule designed to activate chimeric antigen receptor (CAR) effector cells. The switch molecule enhances the safety of CAR-T cell therapies by allowing for the adjustment of CAR-T cell activation in response to severe toxicity. Additionally, it provides a mechanism to target new antigens generated from mutations, thereby improving the effectiveness of cancer treatments.
Career Highlights
Uhlen is currently associated with Abclon Inc., where he continues to advance his research and development efforts. His work focuses on creating innovative solutions that address critical challenges in cancer therapy.
Collaborations
Uhlen collaborates with Jong Seo Lee, contributing to the advancement of their shared goals in the field of biotechnology.
Conclusion
Carl Erik Mathias Uhlen's innovative work in developing switch molecules for CAR-T cell therapies represents a significant advancement in cancer treatment. His contributions are paving the way for more effective and safer therapeutic options for patients.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile